Vistagen Therapeutics Appoints Director Douglas J. Williamson

What Happened Vistagen Therapeutics, Inc. (VTGN) filed an 8-K reporting that on July 29, 2026 the Board unanimously appointed Douglas J. Williamson, M.D. as a director, to serve until the next annual meeting or until his successor is elected. The company granted Dr. Williamson stock options and will provide standard director cash and equity compensation; an indemnification agreement was also executed.

Key Details

• Appointment date: July 29, 2026; press release filed as Exhibit 99.1 on July 31, 2026.
• Option grant: options to purchase 40,826 shares of common stock at an exercise price of $0.2433 per share (the closing price on the appointment date).
• Option terms: 10-year term; vesting in equal annual installments over three years beginning one year after the grant (fully vested on the 3rd anniversary).
• Governance/other: Dr. Williamson will receive annual cash and equity under the Director Compensation Plan; an Indemnification Agreement (Exhibit 10.1) requires the company to indemnify and advance expenses to him to the fullest extent permitted by Nevada law. No related-party transactions or family relationships were reported.

Why It Matters

• Board composition: investors should note a new director joining Vistagen’s board, which can influence governance and oversight.
• Potential dilution: the option grant represents potential issuance of 40,826 shares if exercised (exercise price equals the grant-date closing price, so options were at-the-money at grant). Vesting over three years means the shares would only become available gradually.
• Standard protections: the indemnification agreement is a common protection for directors and signals the company has formal legal protections in place.
• No disclosed conflicts: the filing states there are no related-party transactions or family ties reported with existing management or directors.